JCR Pharmaceuticals Co., Ltd.
Stock Price Chart
2026/08/21 UpdatedPrice Trend
2026/08/21 UpdatedPrice & Trading Details
2026/08/21 UpdatedPRICE
TRADING
Analyst Recommendations 6 analysts
Updated 2026/08/01Earnings Calendar
Updated 2026/08/01Recent Earnings
| Date | EPS Est. | EPS Actual | Surprise |
|---|---|---|---|
| 2026/07/29 | ¥-11.27 | ¥-15.64 | -38.8% |
| 2026/01/28 | ¥-1.07 | ¥0.27 | +125.2% |
| 2025/10/30 | ¥18.67 | ¥18.51 | -0.9% |
| 2025/07/29 | ¥4.36 | ¥-4.48 | -202.8% |
Shareholder Composition
Updated 2026/08/01Top Mutual Funds / ETFs
Updated 2026/08/01Major Holders
Updated 2026/08/01| Fund Name | Ownership | Shares | Change |
|---|---|---|---|
|
VANGUARD STAR FUNDS-Vanguard Total International Stock Index Fund
|
1.1M | +5.62% | |
|
VANGUARD TAX-MANAGED FUNDS-Vanguard Developed Markets Index Fund
|
715.2K | 0.00% | |
|
VANGUARD Intl Eqy. INDEX Fd.S-Vanguard FTSE All-World ex-US Small-Cap
|
303.5K | +11.38% | |
|
SCHWAB STRATEGIC TRUST-Schwab International Small-Cap Equity ETF
|
163.6K | +4.76% | |
|
VANGUARD Intl Eqy. INDEX Fd.S-Vanguard Pacific Stock Index Fd.
|
91.4K | -5.09% | |
|
VANGUARD Intl Eqy. INDEX Fd.S-Vanguard Total World Stock Index Fd.
|
62.9K | 0.00% |
| Institution | Ownership | Shares | Change |
|---|---|---|---|
|
Legato Capital Management LLC
|
10.9K | +1.00% |
Dividend History
Updated 2026/08/23| Year | Dividend | Change |
|---|---|---|
| 2026 | ¥10 | -50.0% |
| 2025 | ¥20 | 0.0% |
| 2024 | ¥20 | 0.0% |
| 2023 | ¥20 | -9.1% |
| 2022 | ¥22 | - |
Financial Performance
2026/08/23 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥51,082M | ¥34,343M | ¥42,871M | ¥33,072M |
| Gross Profit | ¥40,620M | ¥25,456M | ¥31,251M | ¥21,738M |
| Operating Income | ¥19,934M | ¥4,976M | ¥7,532M | -¥6,651M |
| Pretax Income | ¥19,449M | ¥5,456M | ¥7,330M | -¥6,259M |
| Net Income | ¥14,507M | ¥3,772M | ¥5,507M | -¥4,759M |
| EPS | ¥116.80 | ¥30.22 | ¥43.92 | - |
| Operating Margin | 39.02% | 14.49% | 17.57% | -20.11% |
| Balance Sheet | ||||
| Total Assets | ¥97,134M | ¥94,937M | ¥102,226M | ¥104,855M |
| Total Equity | ¥50,881M | ¥52,161M | ¥56,176M | ¥47,040M |
| Total Liabilities | ¥46,253M | ¥42,776M | ¥46,050M | ¥57,815M |
| Cash | ¥30,733M | ¥13,278M | ¥18,756M | ¥13,196M |
| Interest-bearing Debt | ¥18,100M | ¥22,800M | ¥23,300M | ¥38,105M |
| Equity Ratio | 52.38% | 54.94% | 54.95% | 44.86% |
| D/E Ratio | 0.36 | 0.44 | 0.41 | 0.81 |
| Cash Flow | ||||
| Operating CF | ¥9,289M | -¥5,500M | ¥9,312M | -¥5,486M |
| Investing CF | -¥3,250M | -¥15,002M | -¥2,690M | -¥9,874M |
| Financing CF | -¥2,179M | ¥1,948M | -¥2,031M | ¥9,736M |
| Free CF | -¥2,118M | -¥14,060M | ¥7,786M | -¥15,374M |
| Efficiency | ||||
| ROE | 28.51% | 7.23% | 9.80% | -10.12% |
| ROA | 14.94% | 3.97% | 5.39% | -4.54% |
Latest IR Information
-
Q1 FY2027 Financial Results Conference
JCR Pharma achieved net sales of 9,700 million yen in the first quarter of FY2027, a 13.2% increase YoY, with gross profit reaching 7,450 million yen, a 19.9% YoY increase. Research and development expenses and selling expenses also increased, leading...
Read more -
【JCR Pharmaceuticals】2027 Q1 Results｜Sales of 9.7 billion yen (Increase of 13.2% YoY)
JCR Pharmaceuticals achieved sales of 9.7 billion yen (up 13.2% YoY) in the first quarter of fiscal 2027, but recorded losses in operating, ordinary, and net income. Increased research and development expenses and progress in new drug development are expected...
Read more -
Notice of Share Buyback
JCR Pharma announced that it completed the share buyback on July 22, 2026. The shares purchased were common shares, and the total amount spent was 98,496,000 yen. The purpose of the buyback was to improve capital efficiency and return value...
Read more -
Domestic Development Plan for Duchenne Muscular Dystrophy Treatment｜July 2026
JCR Pharma announces its domestic development plan for the Duchenne Muscular Dystrophy treatment drug givinostat, aiming to submit for approval within 2026 and to commence sales within 2027.
Read more
Latest News (5 items)
-
Average Analyst Rating: hold
Average Target Price: ¥600
Rating Score: 2.67 (Based on 6 analysts)
※1=Strong Buy, 5=Strong Sell
Company Information
About
JCR Pharmaceuticals Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, import and export, and sale of pharmaceutical products, biopharmaceuticals, medical equipment, regenerative medicines, and drug substances in Japan. The comany offers various therapeutic products, including GROWJECT used for the treatment of growth hormone deficiency and short stature; IZCARGO to treat Mucopolysaccharidosis type II; Agalsidase Beta BS I.V. Infusion used for the treatment of Fabry disease; and TEMCELL HS Inj used to treat acute graft-versus-host disease. The company develops Epoetin Alfa BS and Darbepoetin Alfa BS Injections for the treatment of renal anemia. In addition, it sells, imports, and exports medical devices; and purchases and sells medical and research equipment. The company has a collaboration agreement with Angelini Pharma for the development of novel biologic therapies; and a joint research agreement with Modalis Therapeutics Corporation to evaluate the drug delivery technology of gene therapy to the central nervous system (CNS) assuming CNS diseases as a target. The company was founded in 1975 and is based in Ashiya, Japan.
